Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 9:2019:2637607.
doi: 10.1155/2019/2637607. eCollection 2019.

The TNFA -857C/T Polymorphism: Association with Rheumatoid Arthritis and Anti-CCP Levels in a Mexican Population

Affiliations

The TNFA -857C/T Polymorphism: Association with Rheumatoid Arthritis and Anti-CCP Levels in a Mexican Population

Juan Manuel Agraz-Cibrián et al. J Immunol Res. .

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease whose association with SNPs has led to the identification of biomarkers in different populations. To determine the association of the -857C/T SNP of the TNFA gene with RA and clinical parameters, 233 RA patients and 237 healthy controls were included in this study. The -857C/T polymorphism was determined using the TaqMan® system and clinical features were also determined. We found that the -857C/T SNP was in Hardy-Weinberg equilibrium. Our results showed no association of the -857C/T SNP with RA; however, RA patients carrying the TT genotype showed lower anti-CCP levels than other groups. Therefore, the TT genotype could be a risk factor for developing anti-CCP-negative RA. Our results suggest that the T allele of the TNFA -857C/T SNP exerts an influence on anti-CCP levels and could be a candidate marker for anti-CCP-negative RA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Anti-CCP levels in RA patients grouped according to their genotype, -857-C/T. Comparisons were performed using the Mann–Whitney U test.

Similar articles

References

    1. Alam J., Jantan I., Bukhari S. N. A. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomedicine & Pharmacotherapy. 2017;92:615–633. doi: 10.1016/j.biopha.2017.05.055. - DOI - PubMed
    1. Burgos-Vargas R., Catoggio L. J., Galarza-Maldonado C., Ostojich K., Cardiel M. H. Current therapies in rheumatoid arthritis: a Latin American perspective. Reumatología Clínica. 2013;9(2):106–112. doi: 10.1016/j.reuma.2012.09.001. - DOI - PubMed
    1. Boissier M.-C., Semerano L., Challal S., Saidenberg-Kermanac'h N., Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. Journal of Autoimmunity. 2012;39(3):222–228. doi: 10.1016/j.jaut.2012.05.021. - DOI - PubMed
    1. Sakkas L. I., Bogdanos D. P., Katsiari C., Platsoucas C. D. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis—relevance to treatment. Autoimmunity Reviews. 2014;13(11):1114–1120. doi: 10.1016/j.autrev.2014.08.012. - DOI - PubMed
    1. Boeters D. M., Gaujoux-Viala C., Constantin A., van der Helm-van Mil A. H. M. The 2010 ACR/EULAR criteria are not sufficiently accurate in the early identification of autoantibody-negative rheumatoid arthritis: results from the Leiden-EAC and ESPOIR cohorts. Seminars in Arthritis and Rheumatism. 2017;47(2):170–174. doi: 10.1016/j.semarthrit.2017.04.009. - DOI - PubMed

MeSH terms

Substances